Login / Signup

Letter: serum HBV RNA and HBcrAg may help to evaluate safely stopping nucleot(s)ide analogues in patients with HBeAg-negative chronic hepatitis B and without cirrhosis.

Meng-Lan WangFa-Da WangEn-Qiang Chen
Published in: Alimentary pharmacology & therapeutics (2022)
Keyphrases
  • hepatitis b virus
  • liver failure
  • molecular docking
  • nucleic acid